AURORA, ON, April 7 /PRNewswire-FirstCall/ - Helix BioPharma Corp. (TSX: HBP / Frankfurt: WKN 918864)
Helix BioPharma Corp. today announced that the board of directors has increased the authorized number of directors from six to seven and has appointed Mr. W. Thomas Hodgson as director to fill the newly created position. Mr. Hodgson will also serve as chair of the three member Audit Committee, replacing Mr. Jack Kay who previously held the position.
Mr. Hodgson is currently senior partner and chairman of Greenbrook Capital Partners and acts as an advisor to the chairman of Magna Entertainment Corp. Mr. Hodgson's prior roles include senior positions with Canadian financial institutions and U.K. based companies.
Donald Segal, chief executive officer of Helix BioPharma, said, "Tom's diverse professional background and capital markets experience will be an invaluable resource to the board. In addition, his extensive knowledge of complex financial matters makes him ideally suited to chair our audit committee. We look forward to his contributions."
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company specializing in
the field of cancer therapy. The company is actively developing innovative
products for the prevention and treatment of cancer based on its
proprietary technologies. Helix's product development initiatives include
its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate.
Helix is listed on the TSX under the symbol "HBP" and quoted on the
Frankfurt, Berlin, Munich and Stuttgart Stock Exchanges under the same
The Toronto Stock Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the content of this News
|SOURCE Helix BioPharma Corp.|
Copyright©2008 PR Newswire.
All rights reserved